Skip to main content
. 2019 Apr;10(2):300–306. doi: 10.21037/jgo.2018.11.08

Table 8. Stage-specific overall survival for mixed adenoneuroendocrine carcinoma.

Overall survival Stage I Stage II Stage III Stage IV
1-year OS 96.6% 86.4% 75%
2-year OS 100% 96.6% 79.7% 41.3%
3-year OS 100% 96.6% 79.7% 26.5%
4-year OS 85.2% 53.2% 26.5%